MX2023008598A - Agentes de interleuquina-2 y usos de los mismos. - Google Patents

Agentes de interleuquina-2 y usos de los mismos.

Info

Publication number
MX2023008598A
MX2023008598A MX2023008598A MX2023008598A MX2023008598A MX 2023008598 A MX2023008598 A MX 2023008598A MX 2023008598 A MX2023008598 A MX 2023008598A MX 2023008598 A MX2023008598 A MX 2023008598A MX 2023008598 A MX2023008598 A MX 2023008598A
Authority
MX
Mexico
Prior art keywords
mutants
interleukin
agents
variants
treat
Prior art date
Application number
MX2023008598A
Other languages
English (en)
Inventor
Zachary Shriver
Gregory Babcock
Boopathy Ramakrishnan
Scott Moore Carlson
Susan Sloan
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of MX2023008598A publication Critical patent/MX2023008598A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se divulgan agentes de IL-2 que comprenden variantes de IL-2, así como métodos, composiciones y usos de los mismos. Los agentes de IL-2 descritos en el presente documento pueden utilizarse para tratar y/o prevenir diversos trastornos y afecciones.
MX2023008598A 2021-01-20 2022-01-20 Agentes de interleuquina-2 y usos de los mismos. MX2023008598A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163139736P 2021-01-20 2021-01-20
US202163281397P 2021-11-19 2021-11-19
PCT/US2022/013141 WO2022159590A1 (en) 2021-01-20 2022-01-20 Interleukin-2 mutants and uses thereof

Publications (1)

Publication Number Publication Date
MX2023008598A true MX2023008598A (es) 2023-08-10

Family

ID=80446172

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008598A MX2023008598A (es) 2021-01-20 2022-01-20 Agentes de interleuquina-2 y usos de los mismos.

Country Status (9)

Country Link
US (1) US20220226442A1 (es)
EP (1) EP4281101A1 (es)
JP (1) JP2024503506A (es)
KR (1) KR20230147072A (es)
AU (1) AU2022211021A1 (es)
CA (1) CA3208934A1 (es)
MX (1) MX2023008598A (es)
TW (1) TW202245825A (es)
WO (1) WO2022159590A1 (es)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
WO1990002809A1 (en) 1988-09-02 1990-03-22 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
JP4146512B2 (ja) 1991-03-01 2008-09-10 ダイアックス コープ． 小型タンパク質
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DK1589107T3 (da) 1992-08-21 2010-04-26 Univ Bruxelles Immonuglobuliner uden lette kæder
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
WO2016164937A2 (en) 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
JP7464389B2 (ja) 2016-08-02 2024-04-09 ビステラ， インコーポレイテッド 操作されたポリペプチドおよびその使用
US10174092B1 (en) * 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
CN114450298A (zh) 2019-07-26 2022-05-06 威特拉公司 白介素-2制剂及其用途

Also Published As

Publication number Publication date
CA3208934A1 (en) 2022-07-28
US20220226442A1 (en) 2022-07-21
WO2022159590A1 (en) 2022-07-28
EP4281101A1 (en) 2023-11-29
TW202245825A (zh) 2022-12-01
AU2022211021A1 (en) 2023-08-03
JP2024503506A (ja) 2024-01-25
KR20230147072A (ko) 2023-10-20

Similar Documents

Publication Publication Date Title
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
PH12020500241A1 (en) Cytokine conjugates for the treatment of autoimmune diseases
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
MX2022009164A (es) N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos.
MX2021002180A (es) Composiciones de inhibidores del receptor de quimiocina c-x-c tipo 4 (cxcr4) y metodos de preparacion y uso.
PH12020551140A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12020551144A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2022002740A (es) Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
WO2022031847A3 (en) Compositions and methods for inhibiting plp1 expression
MX2022012474A (es) Compuestos y usos de estos.
ZA202207804B (en) Compounds and uses thereof
MX2020006355A (es) Pirrolidinamidas ii sustituidas.
WO2018178243A3 (en) Dihydrotetrabenazine for use in the treatment a movement disorder
NZ756936A (en) Composition and method for preventing or delaying onset of myopia comprising atropine
MX2022009308A (es) Compuestos y usos de estos.
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
CR20220656A (es) Unión de anticuerpos multiespecíficos a bcma
MX2022009367A (es) Compuestos y usos de estos.
ZA202209970B (en) Neurotoxin compositions for use in treating cardiovascular disorders
CR20230474A (es) Anticuerpos anti-cd19 y estructuras car-t